Phase III PlanB Final Analysis: Adjuvant TC vs EC→T in Pts With High-Risk HER2-Negative Early Breast Cancer

June 2-6, 2017; Chicago, Illinois

TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.

Format: Microsoft PowerPoint (.ppt)

File Size: 675 KB

Released: June 12, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings